MR, 18F-FDG, and 18F-AV45 PET correlate with AD PSEN1 original phenotype

Alzheimer Disease and Associated Disorders

Volumn 27, Issue 1, 2013, Pages 91-94

  Saint Aubert, Laure ^a,b   Payoux, Pierre ^a,b   Hannequin, Didier ^d,e   Barbeau, Emmanuel J ^b   Campion, Dominique ^d,e   Delisle, Marie Bernadette ^c,d   Tafani, Mathieu ^b,d,e   Viallard, Gérard ^a,b   Péran, Patrice ^a,b   Puel, Michèle ^a,b   Chollet, François ^a,b   Demonet, Jean François ^a,b   Pariente, Jérémie ^a,b,f  

^a CHU PURPAN   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c CHU RANGUEIL   (France)

^d INSERM   (France)

^e ROUEN UNIVERSITY HOSPITAL   (France)

^f LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Alzheimer disease; amyloid; AV45; genetics; MRI; PET

Indexed keywords

FLORBETAPIR F 18; FLUORINE 18; PRESENILIN 1; ANILINE DERIVATIVE; DIAGNOSTIC AGENT; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; FLUORODEOXYGLUCOSE F 18; PSEN1 PROTEIN, HUMAN; RADIOPHARMACEUTICAL AGENT;

ADULT; AGNOSIA; ARTICLE; BRAIN BIOPSY; BRAIN CORTEX ATROPHY; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; COMPARATIVE STUDY; DISEASE COURSE; GENE MUTATION; HUMAN; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SPASTIC PARAPLEGIA; ALZHEIMER DISEASE; BRAIN; GENETICS; METHODOLOGY; PATHOLOGY; SCINTISCANNING;

ADULT; ALZHEIMER DISEASE; ANILINE COMPOUNDS; BRAIN; ETHYLENE GLYCOLS; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; PHENOTYPE; POSITRON-EMISSION TOMOGRAPHY; PRESENILIN-1; RADIOPHARMACEUTICALS;

MLCS; MLOWN;

EID: 84874264604     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e318251d87c     Document Type: Article

References (11)

1. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27:6174-6184.
2. Koivunen J, Verkkoniemi A, Aalto S, et al. PET amyloid ligand [11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain. 2008;131(Pt 7):1845-1853.
3. Lezak MD. Neuropsychological Assessment. New York, NY: Oxford University Press; 2004.
4. Raux G, Guyant-Marechal L, Martin C, et al. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J Med Genet. 2005;42:793-795.
5. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2011;9:1118-1127.
6. Querbes O, Aubry F, Pariente J, et al. Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve. Brain. 2009;132(Pt 8):2036-2047.
7. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305:275-283.
8. Ng SY, Villemagne VL, Masters CL, et al. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh compound B. Arch Neurol. 2007; 64:1140-1144.
9. Johnson KA, Gregas M, Becker JA, et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol. 2007;62:229-234.
10. Chetelat G, Villemagne VL, Bourgeat P, et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67:317-324.
11. Anheim M, Hannequin D, Boulay C, et al. Ataxic variant of Alzheimer's disease caused by Pro117Ala PSEN1 mutation. J Neurol Neurosurg Psychiatry. 2007;78:1414-1415.